The envelope glycoprotein of the mouse mammary tumor virus (MMTV gp52), a useful plasma marker for mammary tumors in mice, was measured in extracellular medium by radioimmunoassay to quantitatively compare gp52 levels released by a C3H MMTV producer and its subcloned B9 nonproducer cell line. Experiments analyzed levels of viral gp52 released from nonproducer cells both in the presence and absence of dexamethasone (DXS) to compare levels with those of producer cells and to assess quantitative changes in nonproducer release of both soluble and virion-associated gp52. Basal gp52 levels of producer cells were 2.4- to 7.0-fold higher than nonproducer cells. Very little virion-associated gp52 was detected in nonproducer cultures, whereas soluble gp52 was abundant and easily detectable in both cultures. DXS stimulated virus production in B9 cultures, converting nonproducer cells into producers. However, under identical conditions of DXS stimulation, B9 cells never reached the same elevated levels of gp52 as producer cells (90 ng/l06 cells versus 216 ng/l06 cells). Significant soluble gp52 release by B9 cells in the absence of DXS and enhancement in the presence of DXS argues that nonproducer cells can inñuence extracellular levels of viral antigen. By analogy to in vivo studies, results suggest that nonproducer cells in a tumor might also contribute to the pool of gp52 which serves as a systemic plasma marker for tumor.

Keywords:
Nonproducer cell, Mouse mammary tumor virus, Tumor marker, Gp52, Dexamethasone
This content is only available via PDF.
© 1989 S. Karger AG, Basel
1989
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.